Lyell Immunopharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held virtually on June 16, 2023. Lyell Immunopharma, Inc. is a Delaware corporation with its principal executive offices in South San Francisco, California. The filing details the voting outcomes for four proposals presented to shareholders.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Shareholders representing 75.25% of outstanding common stock (187,850,683 shares) participated in the meeting. The certified results for the four proposals were as follows:
- Proposal 1 (Election of Directors): All three Class II director nominees (Richard Klausner, M.D., Otis Brawley, M.D., and William Rieflin) were elected. Significant broker non-votes (33,914,284) were recorded for this proposal.
- Proposal 2 (Ratification of Auditors): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, was ratified with 187,794,458 votes for.
- Proposal 3 (Say-on-Pay): The advisory vote to approve executive compensation passed with 131,476,834 votes for, though 19,180,844 votes were abstained.
- Proposal 4 (Say-on-Pay Frequency): Shareholders voted to hold advisory votes on executive compensation annually. 142,962,684 votes were cast for a one-year frequency.
Guidance, Outlook, and Management Commentary
Following the shareholder vote on Proposal 4, the Board of Directors adopted a resolution on June 19, 2023, to hold future stockholder advisory votes on executive compensation on an annual basis. This policy will remain in effect until the next required vote on frequency, which must occur no later than the 2029 Annual Meeting. The filing contains no financial guidance, risk factors, or discussion of contingencies.
Key Facts for Investor Verification
- Verify the specific terms of the executive compensation plan referenced in the Proxy Statement, given the high number of abstentions (approx. 10.2%) on the Say-on-Pay vote.
- Confirm the tenure and background of the newly elected Class II directors (Klausner, Brawley, Rieflin) serving until the 2026 annual meeting.
- Review the definitive Proxy Statement (Schedule 14A filed April 27, 2023) for detailed rationale behind the voting proposals and executive compensation disclosures.
- Note that the filing does not provide updated financial performance data; refer to the most recent 10-Q or 10-K for financial health assessment.